Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2017, Article ID 8584605, 9 pages
https://doi.org/10.1155/2017/8584605
Research Article

The Prognostic Value of Baseline Lymphocyte, Neutrophil, and Monocyte Counts in Locally Advanced Cervical Carcinoma Treated with Radiation

1Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, OH, USA
2Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH, USA
3Division of Gynecologic Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA

Correspondence should be addressed to Sareena Singh; gro.htlaehortem@3hgniss

Received 8 August 2016; Accepted 14 December 2016; Published 23 January 2017

Academic Editor: Enrique Hernandez

Copyright © 2017 Sareena Singh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Y. Shih, A. Yuan, J. J. W. Chen et al., “Tumor-associated macrophage: it's role in cancer invasion and metastasis,” Journal of Cancer Molecules, vol. 2, no. 3, pp. 101–106, 2006. View at Google Scholar
  2. P. C. Fernandes Jr., C. B. Garcia, D. C. Micheli, F. Q. Cunha, E. F. C. Murta, and B. M. Tavares-Murta, “Circulating neutrophils may play a role in the host response in cervical cancer,” International Journal of Gynecological Cancer, vol. 17, no. 5, pp. 1068–1074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. S. Wu, T. Oduyebo, L. P. Cobb et al., “Lymphopenia and its association with survival in patients with locally advanced cervical cancer,” Gynecologic Oncology, vol. 140, no. 1, pp. 76–82, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. N. A. Dewyer, G. T. Wolf, E. Light et al., “Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer,” Head and Neck, vol. 36, no. 1, pp. 9–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Dou, R.-B. Wang, H.-J. Yan et al., “Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 6, pp. 3881–3885, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. H. Huang, J. N. Waldron, M. Milosevic et al., “Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status,” Cancer, vol. 121, no. 4, pp. 545–555, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. Y.-D. Tsai, C.-P. Wang, C.-Y. Chen et al., “Pretreatment circulating monocyte count associated with poor prognosis in patients with oral cavity cancer,” Head and Neck, vol. 36, no. 7, pp. 947–953, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y.-Y. Lee, C. H. Choi, C. O. Sung et al., “Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level,” Gynecologic Oncology, vol. 124, no. 1, pp. 92–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Liang and N. Ferrara, “The complex role of Neutrophils in tumor angiogenesis and metastasis,” Cancer Immunology Research, vol. 4, no. 2, pp. 83–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Carus, M. Ladekarl, H. Hager, B. S. Nedergaard, and F. Donskov, “Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer,” British Journal of Cancer, vol. 108, no. 10, pp. 2116–2122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Wu, Q. Zhao, C. Peng, L. Sun, X.-F. Li, and D.-M. Kuang, “Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop,” Journal of Pathology, vol. 225, no. 3, pp. 438–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Droin, J.-B. Hendra, P. Ducoroy, and E. Solary, “Human defensins as cancer biomarkers and antitumour molecules,” Journal of Proteomics, vol. 72, no. 6, pp. 918–927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Choudhuri, D. Wiseman, M. H. Brown, K. Gould, and P. A. Van Der Merwe, “T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand,” Nature, vol. 436, no. 7050, pp. 578–582, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. J. M. Melief, “Cancer immunotherapy by dendritic cells,” Immunity, vol. 29, no. 3, pp. 372–383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Cheong, I. Matos, J.-H. Choi et al., “Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas,” Cell, vol. 143, no. 3, pp. 416–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Bordon, “Dendritic cells: prime time for monocytes,” Nature Reviews Immunology, vol. 10, no. 12, pp. 808–809, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Sajadieh, M. R. Mouridsen, C. Selmer, T. Intzilakis, O. W. Nielsen, and S. B. Haugaard, “Monocyte number associated with incident cancer and mortality in middle-aged and elderly community-dwelling Danes,” European Journal of Cancer, vol. 47, no. 13, pp. 2015–2022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. S. D. Roxburgh and D. C. McMillan, “Role of systemic inflammatory response in predicting survival in patients with primary operable cancer,” Future Oncology, vol. 6, no. 1, pp. 149–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C. P. Wong, T. M. Bray, and E. Ho, “Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages,” Cancer Letters, vol. 276, no. 1, pp. 38–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G.-O. Ahn and J. M. Brown, “Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells,” Cancer Cell, vol. 13, no. 3, pp. 193–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. E. M. Dirkx, M. G. A. Oude Egbrink, J. Wagstaff, and A. W. Griffioen, “Monocyte/macrophage infiltration in tumors: modulators of angiogenesis,” Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1183–1196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. E. Lewis and J. W. Pollard, “Distinct role of macrophages in different tumor microenvironments,” Cancer Research, vol. 66, no. 2, pp. 605–612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. P. Kudelka, C. F. Verschraegen, and E. Loyer, “Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470,” New England Journal of Medicine, vol. 338, no. 14, pp. 991–992, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. A. P. Kudelka, T. Levy, C. F. Verschraegen et al., “A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix,” Clinical Cancer Research, vol. 3, no. 9, pp. 1501–1505, 1997. View at Google Scholar · View at Scopus
  26. R. A. Cooper, D. P. Wilks, J. P. Logue et al., “High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy,” Clinical Cancer Research, vol. 4, no. 11, pp. 2795–2800, 1998. View at Google Scholar · View at Scopus
  27. K. S. Tewari, M. W. Sill, H. J. Long et al., “Improved survival with bevacizumab in advanced cervical cancer,” The New England Journal of Medicine, vol. 370, pp. 734–743, 2014. View at Google Scholar
  28. T. Boon, P. G. Coulie, and B. Van den Eynde, “Tumor antigens recognized by T cells,” Immunology Today, vol. 18, no. 6, pp. 267–268, 1997. View at Google Scholar · View at Scopus
  29. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18538–18543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Leffers, M. J. M. Gooden, R. A. De Jong et al., “Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 3, pp. 449–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. J. Disaia, C. P. Morrow, A. Hill, and R. N. Lois Mittelstaedt, “Immune competence and survival in patients with advanced cervical cancer: peripheral lymphocyte counts,” International Journal of Radiation Oncology, Biology, Physics, vol. 4, no. 5-6, pp. 449–451, 1978. View at Publisher · View at Google Scholar · View at Scopus
  34. C. H. Choi, H. Kang, W. Y. Kim et al., “Prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 1, pp. 199–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. P. J. Hoskin, A. M. Rojas, S. N. Peiris, V. Mullassery, and I. Y. Chong, “Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix,” Clinical Oncology, vol. 26, no. 4, pp. 179–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Basu, A. O. Mehta, M. M. Jain et al., “ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer,” in Proceedings of the 50th Annual Meeting of American Society Of Clinical Oncology is a Medical, Oncology and Science Meeting (ASCO '14), Chicago, Ill, USA, 2014.
  37. L. A. Fumagalli, J. Vinke, W. Hoff, E. Ypma, F. Brivio, and A. Nespoli, “Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy,” Journal of Immunotherapy, vol. 26, no. 5, pp. 394–402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Schmidt, S. Suciu, C. J. A. Punt et al., “Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1562–1569, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Westermann and R. Pabst, “Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?” Immunology Today, vol. 11, pp. 406–410, 1990. View at Publisher · View at Google Scholar · View at Scopus
  40. K. S. Blum and R. Pabst, “Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs?” Immunology Letters, vol. 108, no. 1, pp. 45–51, 2007. View at Publisher · View at Google Scholar · View at Scopus